Soliqua 100/33 (insulin glargine/lixisenatide) is a brand-name injection pen that’s prescribed to improve blood sugar levels in adults with type 2 diabetes. The drug’s cost, with and without ...
Both products combine a long acting insulin with a GLP-1 analogue – Xultopy brings together Tresiba and Victoza, while Soliqua (formerly known as LixiLan) combines Lantus with Adlyxin (Lxyumia ...
Hosted on MSN6mon
Sanofi Introduces Diabetes Drug Soliqua In IndiaSoliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist. India Has The 2nd ...
In Sanofi’s case, Suliqua combines its Lantus (insulin glargine) with the GLP-1 agonist lixisenatide in an injected, once-daily titratable fixed-ratio combination. Sanofi launched the drug in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback